| |
 |
 |
| 1 |
 |
|
|
 |
| |
 |
Red blood cells (RBCs) have ability to undergo large deformations when subjected to stresses, which allows the RBCs to pass through capillaries narrower than resting RBC diameter.
A slight decrease in red cell deformability may cause important disturbances in the blood circulation of micro-vessels, but also in blood vessels whose lumen is diminished markedly by atherosclerosis or thrombosis.
Recent clinical observations have reported that reduced RBC deformability is a common risk factor for circulation diseases including diabetes, sepsis, malaria, hypertension, sickle cell anemia, myocardial ischaemia, stroke and other circulation disorders. A growing body of scientific evidences indicates that cell deformability can be used to identify patients at risk for cardiovascular diseases at earlier stage.
Cell deformability test - one that is performed at the patient point of care and that delivers results in just a minute - would give healthcare providers a valuable tool for diagnosing and preventing circulation disorders. |
|
|
 |
| 2 |
|
|
|
|
| |
|
In the past, RBC deformability measurements have made a laboratory-setting. Past measurement methods have been required for long measuring time and washing process after use. In order to be clinically useful, cell deformability measurement should be quick and easy as well as no-washing required.
RheoScan system is providing a new technology and device that ensures the accuracy of cell deformability data at the patient point of care, thus allowing for the diagnosis of related diseases and the development of new medicines and treatments. |
|
|
|
| 3 |
|
|
|
|
| |
|
| Ultimately, anyone at risk of developing circulatory disorders will benefit from a better technology for measuring cell deformability. Quick and easy measurements at point of care will provide an earlier detection of the circulatory diseases, allowing patients to be treated on time and to have healthy life. |
|
|
|
| 4 |
|
|
|
|
| |
|
RheoScan received approval from Korea Food & Drug Administration(KFDA) though GMP tests as a First class medical device in Dec., 2005. Furthermore, RheoScan have declared CE for high quality manufacturing and management.
RheoScan formed key partnerships with leading research and medical institutions such as Kyungpook National University Hospital, Korea University Hospital-Artificial Organ Research Center, and has scheduled a number of clinical studies through to further validate the relationship between the biophysical properties of cell deformability and circulatory disorders. |
|
|
|
| 5 |
|
|
|
|
| |
|
| The company holds 5 Korea patents and two international patents. Currently, it has 7 pending patents in the Korea. |
|
|
|
| 6 |
|
|
|
|
| |
|
| The RheoScan-D (RSD) is the first point-of-care device for measuring the biophysical properties of blood cells. By integrating leading-edge technologies such as laser-diffraction, microfluidics, image-processing, RheoScan' innovative disposable ektacytometer measures a patient's blood cell deformability within a minute. The result is a comprehensive blood cell profile that gives the data more clinical practicality. |
|
|
|
| 7 |
|
|
|
|
| |
|
| The RheoScan-D™ consists of a main unit, plastic microchip and a laptop pc. Blood drawn from a patient finger-stick (5 ㎕) is diluted with PBS solution and loaded in a single-use, finely fabricated microchip where it is read by the main unit. The results are presented in la minute via graphical interfaces on the monitor. |
|
|
|
| 8 |
|
|
|
|
| |
|
| The RheoScan-D™ provides RBC deformability data at patient point of care, provides cell deformability information for a patient's blood in real time, and allows for early detection of unrevealed, silent circulatory diseases. |
|
|
|
| 9 |
|
|
|
|
| |
|
| The RheoScan-D™, which is classified as a 1st Class medical device, is approved by KFDA. |
|
|
|
 |
|
| [1]
|
